ANI Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 3/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 108.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ANI Pharmaceuticals Inc's Score
Industry at a Glance
Industry Ranking
3 / 158
Overall Ranking
20 / 4582
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
108.000
Target Price
+32.78%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
ANI Pharmaceuticals Inc Highlights
StrengthsRisks
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 94.19% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 48.52, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 21.97M shares, increasing 0.07% quarter-over-quarter.
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Ticker SymbolANIP
CompanyANI Pharmaceuticals Inc
CEOLalwani (Nikhil Suresh)
Websitehttps://www.anipharmaceuticals.com/
FAQs
What is the current price of ANI Pharmaceuticals Inc (ANIP)?
The current price of ANI Pharmaceuticals Inc (ANIP) is 82.850.
What is the symbol of ANI Pharmaceuticals Inc?
The ticker symbol of ANI Pharmaceuticals Inc is ANIP.
What is the 52-week high of ANI Pharmaceuticals Inc?
The 52-week high of ANI Pharmaceuticals Inc is 99.500.
What is the 52-week low of ANI Pharmaceuticals Inc?
The 52-week low of ANI Pharmaceuticals Inc is 52.500.
What is the market capitalization of ANI Pharmaceuticals Inc?
The market capitalization of ANI Pharmaceuticals Inc is 1.86B.
What is the net income of ANI Pharmaceuticals Inc?
The net income of ANI Pharmaceuticals Inc is -20.15M.
Is ANI Pharmaceuticals Inc (ANIP) currently rated as Buy, Hold, or Sell?
According to analysts, ANI Pharmaceuticals Inc (ANIP) has an overall rating of Buy, with a price target of 108.000.
What is the Earnings Per Share (EPS TTM) of ANI Pharmaceuticals Inc (ANIP)?
The Earnings Per Share (EPS TTM) of ANI Pharmaceuticals Inc (ANIP) is 1.708.